
    
      To evaluate the efficacy and safety by treating the advanced non small cell lung cancer
      (NSCLC) patients who have failure of standard dose EGFR-TKIs(Erlotinib or Gefitinib ) with
      high-dose, pulsatile Erlotinib(450mg every 3 days) or Gefitinib (1000mg every 4 days)
    
  